Luca Gianni

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. doi request reprint Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Luca Gianni
    Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy
    Lancet Oncol 13:25-32. 2012
  2. doi request reprint Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
    Luca Gianni
    Department of Medical Oncology, San Raffaele Institute, Milan, Italy
    Lancet Oncol 12:236-44. 2011
  3. doi request reprint Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Luca Gianni
    Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Lancet 375:377-84. 2010
  4. doi request reprint Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer
    Luca Gianni
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    J Clin Oncol 27:2474-81. 2009
  5. doi request reprint Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Gabriella Mariani
    Department of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Nat Clin Pract Oncol 6:93-104. 2009
  6. ncbi request reprint Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
    Luca Gianni
    Istituto Nazionale Tumori, Milan, Italy, and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 11:8715-21. 2005
  7. ncbi request reprint Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study
    Gabriella Mariani
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Clin Breast Cancer 7:321-5. 2006
  8. doi request reprint Role of anthracyclines in the treatment of early breast cancer
    Luca Gianni
    Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 27:4798-808. 2009
  9. doi request reprint 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
    Aron Goldhirsch
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Lancet 382:1021-8. 2013
  10. doi request reprint International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)
    Alfredo Berruti
    Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Azienda Ospedaliera Universitaria San Luigi di Orbassano, Orbassano, Italy
    J Natl Cancer Inst Monogr 2011:147-51. 2011

Detail Information

Publications22

  1. doi request reprint Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Luca Gianni
    Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy
    Lancet Oncol 13:25-32. 2012
    ..We investigated the combination of pertuzumab or trastuzumab, or both, with docetaxel and the combination of pertuzumab and trastuzumab without chemotherapy in the neoadjuvant setting...
  2. doi request reprint Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
    Luca Gianni
    Department of Medical Oncology, San Raffaele Institute, Milan, Italy
    Lancet Oncol 12:236-44. 2011
    ..We aimed to assess disease-free survival and overall survival after a median follow-up of 4 years for patients enrolled on the Herceptin Adjuvant (HERA) trial...
  3. doi request reprint Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Luca Gianni
    Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Lancet 375:377-84. 2010
    ..We aimed to assess event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without 1 year of trastuzumab...
  4. doi request reprint Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer
    Luca Gianni
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    J Clin Oncol 27:2474-81. 2009
    ..To evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary systemic (neoadjuvant) therapy...
  5. doi request reprint Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Gabriella Mariani
    Department of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Nat Clin Pract Oncol 6:93-104. 2009
    ..Current data do not support the use of trastuzumab for more than 1 year. The analysis of 2-year treatment with trastuzumab is expected to be available in 2009...
  6. ncbi request reprint Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
    Luca Gianni
    Istituto Nazionale Tumori, Milan, Italy, and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 11:8715-21. 2005
    ..We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate...
  7. ncbi request reprint Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study
    Gabriella Mariani
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Clin Breast Cancer 7:321-5. 2006
    ....
  8. doi request reprint Role of anthracyclines in the treatment of early breast cancer
    Luca Gianni
    Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 27:4798-808. 2009
    ..To review data relating to anthracyclines in the adjuvant treatment of early breast cancer...
  9. doi request reprint 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
    Aron Goldhirsch
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Lancet 382:1021-8. 2013
    ....
  10. doi request reprint International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)
    Alfredo Berruti
    Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Azienda Ospedaliera Universitaria San Luigi di Orbassano, Orbassano, Italy
    J Natl Cancer Inst Monogr 2011:147-51. 2011
    ..Changes in tumor biology after PST are an early phenomenon; so, an additional core biopsy performed after 14 days from treatment start should be considered in clinical trials...
  11. pmc Anthracycline cardiotoxicity: from bench to bedside
    Luca Gianni
    Division of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 26:3777-84. 2008
    ..Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues...
  12. ncbi request reprint Anthracyclines
    Luca Gianni
    Division of Medical Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Cancer Chemother Biol Response Modif 21:29-40. 2003
  13. doi request reprint AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer
    Luca Gianni
    Department of Medical Oncology, San Raffaele Hospital, Via Olgettina 60, Milan, Italy
    J Clin Oncol 31:1719-25. 2013
    ..The potential predictive value of plasma VEGF-A is consistent with findings in HER2-negative LR/MBC, warranting prospective evaluation...
  14. doi request reprint Surrogate markers for targeted therapy-based treatment activity and efficacy
    Giampaolo Bianchini
    Department of Medical Oncology, hSR San Raffaele, Via Olgettina 60, Milano 20132, Italy
    J Natl Cancer Inst Monogr 2011:91-4. 2011
    ..Until now, clinically useful and validated predictive markers for targeted therapy are rare, but appropriate investigations in neoadjuvant studies will likely change this...
  15. doi request reprint Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer
    Giampaolo Bianchini
    Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cancer Res 70:8852-62. 2010
    ..Taken together, our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype...
  16. doi request reprint Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours
    Nicola Nicolai
    Urology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    BJU Int 104:340-6. 2009
    ....
  17. doi request reprint Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
    Aleix Prat
    Authors Affiliations Translational Genomics Group, Vall d Hebron Institute of Oncology Department of Medicine, Universitat Autonoma de Barcelona, Barcelona Hospital Clinico Universitario, Valencia, Spain Oncología Médica, San Raffaele Cancer Centre, Milan, Italy Roche, Pharma Research and Early Development, Penzberg Frauenklinik vom Roten Kreuz, Munich, Germany University of North Carolina, Chapel Hill, North Carolina NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation NN Blokhin Russian Cancer Centre Central Clinical Hospital named after N A Semashko, Moscow, Russia and Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 20:511-21. 2014
    ....
  18. ncbi request reprint Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer
    Gianni Bonadonna
    Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    J Clin Oncol 22:1614-20. 2004
    ..To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of disease relapse...
  19. ncbi request reprint Targeting TRAIL agonistic receptors for cancer therapy
    Carmelo Carlo-Stella
    Cristina Gandini Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 13:2313-7. 2007
    ..The clinical translation of cell and gene therapy approaches represent a challenging strategy that might achieve systemic tumor targeting and increased intratumor delivery of the therapeutic agent...
  20. doi request reprint Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples
    Maurizio Callari
    Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    PLoS ONE 9:e86511. 2014
    ..Tools for the implementation of our data processing algorithm are made publicly available at http://www.biocut.unito.it/cdf-ffpe/. ..
  21. doi request reprint The immune system and response to HER2-targeted treatment in breast cancer
    Giampaolo Bianchini
    Department of Medical Oncology, Ospedale San Raffaele, 20132 Milan, Italy
    Lancet Oncol 15:e58-68. 2014
    ....
  22. ncbi request reprint Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer
    Giulia Bianchi
    Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 9:5944-51. 2003
    ..This pilot study evaluates the efficacy and cardiac tolerability of AT followed by paclitaxel with trastuzumab started with AT or paclitaxel alone and investigates pharmacokinetic interactions...